1 / 2

HIV Drugs Market Size & Share

HIV Drugs Market Size & Share

Manisha109
Download Presentation

HIV Drugs Market Size & Share

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HIV Drugs Market Analysis 2024-2032 Market Overview The global HIV drugs market size reached $34.13 billion in 2023 and is projected to grow from $36.11 billion in 2024 to $58.24 billion by 2032, with a compound annual growth rate (CAGR) of 6.2%. Regional Leadership North America dominates with 70.58% market share in 2023, while Asia Pacific shows the fastest growth potential. According to the World Health Organization, Africa accounts for two-thirds of global HIV infections as of 2022, with 630,000 HIV-related deaths reported that year. Key Market Drivers  Rising HIV prevalence: 39 million people lived with HIV infection by end of 20221  Increasing drug approvals and launches  Growing R&D investments in long-acting treatments  Expanding access to treatment in developing nations Major Industry Developments Recent significant developments include:  December 2023: Zydus Lifesciences received FDA approval for Darunavir Tablets (600mg and 800mg) for HIV-1 treatment  August 2023: Aurobindo Pharma announced plans to introduce HIV drugs for children across 123 countries  June 2023: Lupin Limited launched Darunavir Tablets in the U.S. market Leading Companies Key market players include:  ViiV Healthcare  Gilead Sciences, Inc.  GlaxoSmithKline plc  Merck & Co., Inc.  Bristol-Myers Squibb Company  Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)  Boehringer Ingelheim International GmbH  AbbVie Inc.  F. Hoffmann-La Roche AG  Mylan N.V.

  2. Market Segments By Product Type  Combination HIV Medicines (largest segment)  Integrase Inhibitors  Non-nucleoside Reverse Transcriptase Inhibitors (NRTIs)  Others By Distribution Channel  Hospital Pharmacies (dominant segment)  Retail Pharmacies  Online Pharmacies  Others COVID-19 Impact The pandemic initially disrupted drug supply chains and reduced new patient prescriptions. Major companies reported decreased sales, including Gilead Sciences' lower Truvada sales volume and Theratechnologies' reduced Trogarzo sales in European markets. However, the market has shown strong post-pandemic recovery. Future Trends The market is seeing increased focus on:  Long-acting suppression antiretroviral therapies (ATLAS)  Injectable HIV treatments  Strategic collaborations between global and regional players  Enhanced drug accessibility in developing regions Report: HIV Drugs Market Size & Growth | Global Report [2024-2032] https://www.fortunebusinessinsights.com/industry-reports/hiv-aids-drugs-market-101115

More Related